ID   AK1BA_HUMAN             Reviewed;         316 AA.
AC   O60218; A4D1P1; O75890; Q6FHF3; Q8IWZ1;
DT   10-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   08-FEB-2011, sequence version 2.
DT   28-JUN-2023, entry version 196.
DE   RecName: Full=Aldo-keto reductase family 1 member B10;
DE            EC=1.1.1.300 {ECO:0000269|PubMed:12732097};
DE            EC=1.1.1.54 {ECO:0000269|PubMed:19563777};
DE   AltName: Full=ARL-1 {ECO:0000303|PubMed:9565553};
DE   AltName: Full=Aldose reductase-like;
DE   AltName: Full=Aldose reductase-related protein;
DE            Short=ARP;
DE            Short=hARP;
DE   AltName: Full=Small intestine reductase;
DE            Short=SI reductase;
GN   Name=AKR1B10; Synonyms=AKR1B11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANT ASP-313, FUNCTION, TISSUE SPECIFICITY,
RP   AND INDUCTION.
RC   TISSUE=Liver tumor;
RX   PubMed=9565553; DOI=10.1074/jbc.273.19.11429;
RA   Cao D., Fan S.T., Chung S.S.M.;
RT   "Identification and characterization of a novel human aldose reductase-like
RT   gene.";
RL   J. Biol. Chem. 273:11429-11435(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Small intestine;
RX   PubMed=9765596; DOI=10.1016/s0167-4781(98)00109-2;
RA   Hyndman D.J., Flynn T.G.;
RT   "Sequence and expression levels in human tissues of a new member of the
RT   aldo-keto reductase family.";
RL   Biochim. Biophys. Acta 1399:198-202(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASP-313.
RA   Heringlake S.;
RT   "Representational difference analysis based identification and full-length
RT   sequencing of a gene of the aldo-ketoreductase family strongly
RT   overexpressed in hepatocellular carcinoma.";
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-313.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-313.
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-313.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 232-316, AND VARIANT ASP-313.
RX   PubMed=9537432; DOI=10.1002/hep.510270408;
RA   Scuric Z., Stain S.C., Anderson W.F., Hwang J.-J.;
RT   "New member of aldose reductase family proteins overexpressed in human
RT   hepatocellular carcinoma.";
RL   Hepatology 27:943-950(1998).
RN   [11]
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY REGULATION,
RP   FUNCTION, AND SUBSTRATE SPECIFICITY.
RX   PubMed=12732097; DOI=10.1042/bj20021818;
RA   Crosas B., Hyndman D.J., Gallego O., Martras S., Pares X., Flynn T.G.,
RA   Farres J.;
RT   "Human aldose reductase and human small intestine aldose reductase are
RT   efficient retinal reductases: consequences for retinoid metabolism.";
RL   Biochem. J. 373:973-979(2003).
RN   [12]
RP   INDUCTION.
RX   PubMed=15755999; DOI=10.1158/1078-0432.ccr-04-1238;
RA   Fukumoto S., Yamauchi N., Moriguchi H., Hippo Y., Watanabe A.,
RA   Shibahara J., Taniguchi H., Ishikawa S., Ito H., Yamamoto S., Iwanari H.,
RA   Hironaka M., Ishikawa Y., Niki T., Sohara Y., Kodama T., Nishimura M.,
RA   Fukayama M., Dosaka-Akita H., Aburatani H.;
RT   "Overexpression of the aldo-keto reductase family protein AKR1B10 is highly
RT   correlated with smokers' non-small cell lung carcinomas.";
RL   Clin. Cancer Res. 11:1776-1785(2005).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-125 AND LYS-263, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21585341; DOI=10.1042/bj20110111;
RA   Luo D.X., Huang M.C., Ma J., Gao Z., Liao D.F., Cao D.;
RT   "Aldo-keto reductase family 1, member B10 is secreted through a lysosome-
RT   mediated non-classical pathway.";
RL   Biochem. J. 438:71-80(2011).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=19563777; DOI=10.1016/j.bbrc.2009.06.123;
RA   Zhong L., Liu Z., Yan R., Johnson S., Zhao Y., Fang X., Cao D.;
RT   "Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-
RT   derived alpha, beta-unsaturated carbonyls at physiological levels.";
RL   Biochem. Biophys. Res. Commun. 387:245-250(2009).
RN   [16]
RP   FUNCTION, MUTAGENESIS OF CYS-299, CATALYTIC ACTIVITY, SUBSTRATE
RP   SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19013440; DOI=10.1016/j.cbi.2008.10.021;
RA   Martin H.J., Maser E.;
RT   "Role of human aldo-keto-reductase AKR1B10 in the protection against toxic
RT   aldehydes.";
RL   Chem. Biol. Interact. 178:145-150(2009).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) IN COMPLEX WITH TOLRESTAT AND NADP,
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY REGULATION, CATALYTIC
RP   ACTIVITY, AND MUTAGENESIS OF LYS-125 AND VAL-301.
RX   PubMed=18087047; DOI=10.1073/pnas.0705659105;
RA   Gallego O., Ruiz F.X., Ardevol A., Dominguez M., Alvarez R., de Lera A.R.,
RA   Rovira C., Farres J., Fita I., Pares X.;
RT   "Structural basis for the high all-trans-retinaldehyde reductase activity
RT   of the tumor marker AKR1B10.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:20764-20769(2007).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-313, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Catalyzes the NADPH-dependent reduction of a wide variety of
CC       carbonyl-containing compounds to their corresponding alcohols
CC       (PubMed:9565553, PubMed:18087047, PubMed:12732097, PubMed:19013440,
CC       PubMed:19563777). Displays strong enzymatic activity toward all-trans-
CC       retinal, 9-cis-retinal, and 13-cis-retinal (PubMed:12732097,
CC       PubMed:18087047). Plays a critical role in detoxifying dietary and
CC       lipid-derived unsaturated carbonyls, such as crotonaldehyde, 4-
CC       hydroxynonenal, trans-2-hexenal, trans-2,4-hexadienal and their
CC       glutathione-conjugates carbonyls (GS-carbonyls) (PubMed:19013440,
CC       PubMed:19563777). Displays no reductase activity towards glucose
CC       (PubMed:12732097). {ECO:0000269|PubMed:12732097,
CC       ECO:0000269|PubMed:18087047, ECO:0000269|PubMed:19013440,
CC       ECO:0000269|PubMed:19563777, ECO:0000269|PubMed:9565553}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=all-trans-retinol + NADP(+) = all-trans-retinal + H(+) +
CC         NADPH; Xref=Rhea:RHEA:25033, ChEBI:CHEBI:15378, ChEBI:CHEBI:17336,
CC         ChEBI:CHEBI:17898, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.300; Evidence={ECO:0000269|PubMed:12732097,
CC         ECO:0000269|PubMed:18087047};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=9-cis-retinol + NADP(+) = 9-cis-retinal + H(+) + NADPH;
CC         Xref=Rhea:RHEA:54916, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:78272, ChEBI:CHEBI:78273;
CC         Evidence={ECO:0000269|PubMed:12732097, ECO:0000269|PubMed:18087047};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=13-cis-retinol + NADP(+) = 13-cis-retinal + H(+) + NADPH;
CC         Xref=Rhea:RHEA:54920, ChEBI:CHEBI:15378, ChEBI:CHEBI:45479,
CC         ChEBI:CHEBI:45487, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:12732097};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=allyl alcohol + NADP(+) = acrolein + H(+) + NADPH;
CC         Xref=Rhea:RHEA:12168, ChEBI:CHEBI:15368, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16605, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.54;
CC         Evidence={ECO:0000269|PubMed:19563777};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(E)-4-hydroxynon-2-en-1-ol + NADP(+) = (E)-4-hydroxynon-2-enal
CC         + H(+) + NADPH; Xref=Rhea:RHEA:58416, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:58968,
CC         ChEBI:CHEBI:142617; Evidence={ECO:0000269|PubMed:19013440};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 4-hydroxynonen-1-ol + NADP(+) = a 4-hydroxynonenal + H(+) +
CC         NADPH; Xref=Rhea:RHEA:58336, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:142593, ChEBI:CHEBI:142606;
CC         Evidence={ECO:0000269|PubMed:19563777};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=NADP(+) + prenol = 3-methyl-2-butenal + H(+) + NADPH;
CC         Xref=Rhea:RHEA:58420, ChEBI:CHEBI:15378, ChEBI:CHEBI:15825,
CC         ChEBI:CHEBI:16019, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:19563777};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(E)-hex-2-en-1-ol + NADP(+) = (E)-hex-2-enal + H(+) + NADPH;
CC         Xref=Rhea:RHEA:58424, ChEBI:CHEBI:15378, ChEBI:CHEBI:28913,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:141205;
CC         Evidence={ECO:0000269|PubMed:19563777};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(E,E)-2,4-hexadien-1-ol + NADP(+) = (E,E)-2,4-hexadienal +
CC         H(+) + NADPH; Xref=Rhea:RHEA:58428, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:82334,
CC         ChEBI:CHEBI:142625; Evidence={ECO:0000269|PubMed:19563777};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(E)-4-oxonon-2-en-1-ol + NADP(+) = (E)-4-oxonon-2-enal + H(+)
CC         + NADPH; Xref=Rhea:RHEA:58432, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:58972, ChEBI:CHEBI:142624;
CC         Evidence={ECO:0000269|PubMed:19013440};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=4-methylpentan-1-ol + NADP(+) = 4-methylpentanal + H(+) +
CC         NADPH; Xref=Rhea:RHEA:58436, ChEBI:CHEBI:15378, ChEBI:CHEBI:17998,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:63910;
CC         Evidence={ECO:0000269|PubMed:19013440};
CC   -!- ACTIVITY REGULATION: Retinaldehyde reductase activity is inhibited by
CC       tolrestat. {ECO:0000269|PubMed:12732097, ECO:0000269|PubMed:18087047}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6000 uM for D,L-glyceraldehyde {ECO:0000269|PubMed:18087047};
CC         KM=0.6 uM for all-trans-retinal {ECO:0000269|PubMed:18087047};
CC         KM=0.7 uM for 9-cis-retinal {ECO:0000269|PubMed:18087047};
CC         KM=37 uM for pyridine-3-aldehyde {ECO:0000269|PubMed:12732097};
CC         KM=110 uM for acrolein {ECO:0000269|PubMed:19563777};
CC         KM=87 uM for 3-methyl-2-butenal {ECO:0000269|PubMed:19563777};
CC         KM=30 uM for 4-hydroxynonenal {ECO:0000269|PubMed:19563777};
CC         KM=61 uM for (E)-2-hexenal {ECO:0000269|PubMed:19563777};
CC         KM=95 uM for (E,E)-2,4-hexadienal {ECO:0000269|PubMed:19563777};
CC         KM=532 uM for GS-acrolein {ECO:0000269|PubMed:19563777};
CC         KM=245 uM for GS-3-methyl-2-butenal {ECO:0000269|PubMed:19563777};
CC         KM=145 uM for GS-(E)-2-hexenal {ECO:0000269|PubMed:19563777};
CC         KM=77 uM for GS-(E,E)-2,4-hexadienal {ECO:0000269|PubMed:19563777};
CC         KM=330 uM for (E)-4-hydroxynon-2-enal {ECO:0000269|PubMed:19013440};
CC         KM=300 uM for (E)-4-oxonon-2-enal {ECO:0000269|PubMed:19013440};
CC         KM=50 uM for 4-methylpentanal {ECO:0000269|PubMed:19013440};
CC         Vmax=3122 nmol/min/mg enzyme with acrolein
CC         {ECO:0000269|PubMed:19563777};
CC         Vmax=2647 nmol/min/mg enzyme with 3-methyl-2-butenal as substrate
CC         {ECO:0000269|PubMed:19563777};
CC         Vmax=2658 nmol/min/mg enzyme with (E)-2-hexenal as substrate
CC         {ECO:0000269|PubMed:19563777};
CC         Vmax=2160 nmol/min/mg enzyme with (E,E)-2,4-hexadienal as substrate
CC         {ECO:0000269|PubMed:19563777};
CC         Vmax=3298 nmol/min/mg enzyme with 4-hydroxynonenal
CC         {ECO:0000269|PubMed:19563777};
CC         Vmax=64 nmol/min/mg enzyme with GS-acrolein
CC         {ECO:0000269|PubMed:19563777};
CC         Vmax=1960 nmol/min/mg enzyme with GS-3-methyl-2-butenal as substrate
CC         {ECO:0000269|PubMed:19563777};
CC         Vmax=2049 nmol/min/mg enzyme with GS-(E)-2-hexenal
CC         {ECO:0000269|PubMed:19563777};
CC         Vmax=4004 nmol/min/mg enzyme with GS-(E,E)-2,4-hexadienal as
CC         substrate {ECO:0000269|PubMed:19563777};
CC         Note=kcat is 640 min(-1) for glyceraldehyde as substrate
CC         (PubMed:12732097). kcat is 185 min(-1) for pyridine-3-aldehyde as
CC         substrate (PubMed:12732097). kcat is 116 min(-1) for acrolein as
CC         substrate. kcat is 103 min(-1) for 3-methyl-2-butenal as substrate.
CC         kcat is 97 min(-1) for(E)-2-hexenal as substrate. kcat is 82 min(-1)
CC         for (E,E)-2,4-hexadienal as substrate. kcat is 120 min(-1) for
CC         4-hydroxynonenal as substrate. kcat is 3 min(-1) for GS-acrolein as
CC         substrate. kcat is 70 min(-1) for GS-3-methyl-2-butenal as substrate.
CC         kcat is 71 min(-1) for GS-(E)-2-hexenal as substrate. kcat is 147
CC         min(-1) for (E,E)-2,4-hexadienal as substrate (PubMed:19563777). kcat
CC         is 35 min(-1) for D,L-glyceraldehyde as substrate. kcat is 27 min(-1)
CC         for all-trans-retinal as substrate. kcat is 1 min(-1) for
CC         9-cis-retinal as substrate (PubMed:18087047). kcat is 43 min(-1) for
CC         4-hydroxynon-2-enal (PubMed:19013440). kcat is 40 min(-1) for
CC         (E)-4-oxonon-2-enal (PubMed:19013440). kcat is 25 min(-1) for
CC         4-methylpentanal (PubMed:19013440). {ECO:0000269|PubMed:12732097,
CC         ECO:0000269|PubMed:18087047, ECO:0000269|PubMed:19013440,
CC         ECO:0000269|PubMed:19563777};
CC   -!- PATHWAY: Cofactor metabolism; retinol metabolism.
CC       {ECO:0000269|PubMed:12732097, ECO:0000269|PubMed:18087047}.
CC   -!- INTERACTION:
CC       O60218; Q13085: ACACA; NbExp=4; IntAct=EBI-1572139, EBI-717681;
CC       O60218; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-1572139, EBI-750109;
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:21585341}. Secreted
CC       {ECO:0000269|PubMed:21585341}. Note=Secreted through a lysosome-
CC       mediated non-classical pathway.
CC   -!- TISSUE SPECIFICITY: Found in many tissues. Highly expressed in small
CC       intestine, colon and adrenal gland. {ECO:0000269|PubMed:9565553}.
CC   -!- INDUCTION: Overexpressed in certain types of cancers, including
CC       hepatocellular carcinoma and lung cancer associated with tobacco
CC       smoking. {ECO:0000269|PubMed:15755999, ECO:0000269|PubMed:9565553}.
CC   -!- MISCELLANEOUS: Has no counterpart in murine and rat species.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the aldo/keto reductase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U37100; AAC17469.1; -; mRNA.
DR   EMBL; AF052577; AAC36465.1; -; mRNA.
DR   EMBL; AF524864; AAO13380.1; -; mRNA.
DR   EMBL; BT006794; AAP35440.1; -; mRNA.
DR   EMBL; CR541801; CAG46600.1; -; mRNA.
DR   EMBL; AC078847; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236950; EAL24069.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83816.1; -; Genomic_DNA.
DR   EMBL; BC008837; AAH08837.1; -; mRNA.
DR   EMBL; AF044961; AAC15671.1; -; mRNA.
DR   CCDS; CCDS5832.1; -.
DR   RefSeq; NP_064695.3; NM_020299.4.
DR   PDB; 1ZUA; X-ray; 1.25 A; X=1-316.
DR   PDB; 4GA8; X-ray; 1.94 A; A=1-316.
DR   PDB; 4GAB; X-ray; 1.60 A; A=1-316.
DR   PDB; 4GQ0; X-ray; 2.10 A; A=1-316.
DR   PDB; 4GQG; X-ray; 1.92 A; A=1-316.
DR   PDB; 4I5X; X-ray; 2.10 A; A=1-316.
DR   PDB; 4ICC; X-ray; 1.75 A; X=1-316.
DR   PDB; 4JIH; X-ray; 2.30 A; A=1-316.
DR   PDB; 4JII; X-ray; 2.20 A; X=1-316.
DR   PDB; 4WEV; X-ray; 1.45 A; X=1-316.
DR   PDB; 4XZL; X-ray; 1.70 A; X=1-316.
DR   PDB; 4XZM; X-ray; 1.75 A; X=1-316.
DR   PDB; 4XZN; X-ray; 1.70 A; X=1-316.
DR   PDB; 5LIK; X-ray; 2.05 A; X=1-316.
DR   PDB; 5LIU; X-ray; 1.75 A; X=1-316.
DR   PDB; 5LIW; X-ray; 1.75 A; X=1-316.
DR   PDB; 5LIX; X-ray; 1.95 A; X=1-316.
DR   PDB; 5LIY; X-ray; 2.05 A; X=1-316.
DR   PDB; 5M2F; X-ray; 1.50 A; X=1-316.
DR   PDB; 5Y7N; X-ray; 2.50 A; A=1-316.
DR   PDBsum; 1ZUA; -.
DR   PDBsum; 4GA8; -.
DR   PDBsum; 4GAB; -.
DR   PDBsum; 4GQ0; -.
DR   PDBsum; 4GQG; -.
DR   PDBsum; 4I5X; -.
DR   PDBsum; 4ICC; -.
DR   PDBsum; 4JIH; -.
DR   PDBsum; 4JII; -.
DR   PDBsum; 4WEV; -.
DR   PDBsum; 4XZL; -.
DR   PDBsum; 4XZM; -.
DR   PDBsum; 4XZN; -.
DR   PDBsum; 5LIK; -.
DR   PDBsum; 5LIU; -.
DR   PDBsum; 5LIW; -.
DR   PDBsum; 5LIX; -.
DR   PDBsum; 5LIY; -.
DR   PDBsum; 5M2F; -.
DR   PDBsum; 5Y7N; -.
DR   AlphaFoldDB; O60218; -.
DR   SMR; O60218; -.
DR   BioGRID; 121325; 57.
DR   IntAct; O60218; 16.
DR   STRING; 9606.ENSP00000352584; -.
DR   BindingDB; O60218; -.
DR   ChEMBL; CHEMBL5983; -.
DR   DrugBank; DB06246; Exisulind.
DR   DrugBank; DB02021; Fidarestat.
DR   DrugBank; DB06077; Lumateperone.
DR   DrugBank; DB03461; Nicotinamide adenine dinucleotide phosphate.
DR   DrugBank; DB00605; Sulindac.
DR   DrugBank; DB02383; Tolrestat.
DR   DrugBank; DB08772; Zopolrestat.
DR   DrugCentral; O60218; -.
DR   SwissLipids; SLP:000001873; -.
DR   GlyGen; O60218; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O60218; -.
DR   PhosphoSitePlus; O60218; -.
DR   BioMuta; AKR1B10; -.
DR   DOSAC-COBS-2DPAGE; O60218; -.
DR   EPD; O60218; -.
DR   jPOST; O60218; -.
DR   MassIVE; O60218; -.
DR   MaxQB; O60218; -.
DR   PaxDb; O60218; -.
DR   PeptideAtlas; O60218; -.
DR   PRIDE; O60218; -.
DR   ProteomicsDB; 49247; -.
DR   Antibodypedia; 18084; 404 antibodies from 34 providers.
DR   DNASU; 57016; -.
DR   Ensembl; ENST00000359579.5; ENSP00000352584.4; ENSG00000198074.10.
DR   GeneID; 57016; -.
DR   KEGG; hsa:57016; -.
DR   MANE-Select; ENST00000359579.5; ENSP00000352584.4; NM_020299.5; NP_064695.3.
DR   UCSC; uc003vrr.4; human.
DR   AGR; HGNC:382; -.
DR   CTD; 57016; -.
DR   DisGeNET; 57016; -.
DR   GeneCards; AKR1B10; -.
DR   HGNC; HGNC:382; AKR1B10.
DR   HPA; ENSG00000198074; Tissue enhanced (esophagus, intestine, stomach).
DR   MIM; 604707; gene.
DR   neXtProt; NX_O60218; -.
DR   OpenTargets; ENSG00000198074; -.
DR   PharmGKB; PA24676; -.
DR   VEuPathDB; HostDB:ENSG00000198074; -.
DR   eggNOG; KOG1577; Eukaryota.
DR   GeneTree; ENSGT00940000154773; -.
DR   HOGENOM; CLU_023205_0_0_1; -.
DR   InParanoid; O60218; -.
DR   OMA; ACATNQV; -.
DR   OrthoDB; 890110at2759; -.
DR   PhylomeDB; O60218; -.
DR   TreeFam; TF106492; -.
DR   BRENDA; 1.1.1.21; 2681.
DR   PathwayCommons; O60218; -.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SABIO-RK; O60218; -.
DR   SignaLink; O60218; -.
DR   UniPathway; UPA00912; -.
DR   BioGRID-ORCS; 57016; 9 hits in 1111 CRISPR screens.
DR   ChiTaRS; AKR1B10; human.
DR   EvolutionaryTrace; O60218; -.
DR   GeneWiki; AKR1B10; -.
DR   GenomeRNAi; 57016; -.
DR   Pharos; O60218; Tchem.
DR   PRO; PR:O60218; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; O60218; protein.
DR   Bgee; ENSG00000198074; Expressed in jejunal mucosa and 136 other tissues.
DR   Genevisible; O60218; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0008106; F:alcohol dehydrogenase (NADP+) activity; IDA:UniProtKB.
DR   GO; GO:0004032; F:alditol:NADP+ 1-oxidoreductase activity; IBA:GO_Central.
DR   GO; GO:0004033; F:aldo-keto reductase (NADP) activity; TAS:UniProtKB.
DR   GO; GO:0047655; F:allyl-alcohol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0045550; F:geranylgeranyl reductase activity; IDA:UniProtKB.
DR   GO; GO:0047718; F:indanol dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0052650; F:NADP-retinol dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0001758; F:retinal dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0110095; P:cellular detoxification of aldehyde; IDA:UniProtKB.
DR   GO; GO:0044597; P:daunorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0044598; P:doxorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0016488; P:farnesol catabolic process; IDA:UniProtKB.
DR   GO; GO:0001523; P:retinoid metabolic process; IDA:UniProtKB.
DR   CDD; cd19107; AKR_AKR1B1-19; 1.
DR   Gene3D; 3.20.20.100; NADP-dependent oxidoreductase domain; 1.
DR   InterPro; IPR020471; AKR.
DR   InterPro; IPR018170; Aldo/ket_reductase_CS.
DR   InterPro; IPR023210; NADP_OxRdtase_dom.
DR   InterPro; IPR036812; NADP_OxRdtase_dom_sf.
DR   PANTHER; PTHR11732:SF278; ALDO-KETO REDUCTASE FAMILY 1 MEMBER B10; 1.
DR   PANTHER; PTHR11732; ALDO/KETO REDUCTASE; 1.
DR   Pfam; PF00248; Aldo_ket_red; 1.
DR   PIRSF; PIRSF000097; AKR; 1.
DR   PRINTS; PR00069; ALDKETRDTASE.
DR   SUPFAM; SSF51430; NAD(P)-linked oxidoreductase; 1.
DR   PROSITE; PS00798; ALDOKETO_REDUCTASE_1; 1.
DR   PROSITE; PS00062; ALDOKETO_REDUCTASE_2; 1.
DR   PROSITE; PS00063; ALDOKETO_REDUCTASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Lipid metabolism; Lysosome; NADP;
KW   Oxidoreductase; Reference proteome; Secreted.
FT   CHAIN           1..316
FT                   /note="Aldo-keto reductase family 1 member B10"
FT                   /id="PRO_0000124632"
FT   ACT_SITE        49
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   BINDING         20..22
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   BINDING         44
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   BINDING         111
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   BINDING         160..161
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   BINDING         184
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   BINDING         210..217
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   BINDING         261..273
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   SITE            78
FT                   /note="Lowers pKa of active site Tyr"
FT                   /evidence="ECO:0000250|UniProtKB:P14550"
FT   MOD_RES         125
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         263
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   VARIANT         87
FT                   /note="P -> S (in dbSNP:rs2303312)"
FT                   /id="VAR_020077"
FT   VARIANT         286
FT                   /note="M -> T (in dbSNP:rs3735042)"
FT                   /id="VAR_020078"
FT   VARIANT         313
FT                   /note="N -> D (in dbSNP:rs4728329)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:9537432, ECO:0000269|PubMed:9565553,
FT                   ECO:0000269|Ref.3, ECO:0000269|Ref.4, ECO:0000269|Ref.5,
FT                   ECO:0007744|PubMed:21269460"
FT                   /id="VAR_013287"
FT   MUTAGEN         125
FT                   /note="K->L: Increased affinity and reduced catalytic
FT                   activity towards all-trans-retinaldehyde."
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   MUTAGEN         299
FT                   /note="C->S: Decreased affinity and reduced catalytic
FT                   activity towards 4-hydroxynonenal."
FT                   /evidence="ECO:0000269|PubMed:19013440"
FT   MUTAGEN         301
FT                   /note="V->L: Reduced catalytic activity towards
FT                   all-trans-retinaldehyde."
FT                   /evidence="ECO:0000269|PubMed:18087047"
FT   CONFLICT        76
FT                   /note="V -> A (in Ref. 3; AAO13380)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        100
FT                   /note="L -> P (in Ref. 3; AAO13380)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288
FT                   /note="T -> I (in Ref. 3; AAO13380)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..6
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   TURN            8..10
FT                   /evidence="ECO:0007829|PDB:5Y7N"
FT   STRAND          12..19
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   TURN            25..27
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           28..37
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   STRAND          42..44
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           47..49
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           52..64
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           70..72
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   STRAND          74..79
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           81..83
FT                   /evidence="ECO:0007829|PDB:4WEV"
FT   HELIX           86..100
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   STRAND          105..111
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   STRAND          118..120
FT                   /evidence="ECO:0007829|PDB:4WEV"
FT   STRAND          127..131
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           138..150
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   STRAND          153..161
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           164..171
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   STRAND          181..186
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           194..202
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   STRAND          206..211
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   STRAND          223..225
FT                   /evidence="ECO:0007829|PDB:5Y7N"
FT   HELIX           228..230
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           232..240
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           245..254
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   TURN            255..257
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           267..274
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           283..290
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   HELIX           302..304
FT                   /evidence="ECO:0007829|PDB:1ZUA"
FT   STRAND          305..307
FT                   /evidence="ECO:0007829|PDB:4GAB"
FT   HELIX           311..313
FT                   /evidence="ECO:0007829|PDB:4GAB"
SQ   SEQUENCE   316 AA;  36020 MW;  0C2FC0E798955A33 CRC64;
     MATFVELSTK AKMPIVGLGT WKSPLGKVKE AVKVAIDAGY RHIDCAYVYQ NEHEVGEAIQ
     EKIQEKAVKR EDLFIVSKLW PTFFERPLVR KAFEKTLKDL KLSYLDVYLI HWPQGFKSGD
     DLFPKDDKGN AIGGKATFLD AWEAMEELVD EGLVKALGVS NFSHFQIEKL LNKPGLKYKP
     VTNQVECHPY LTQEKLIQYC HSKGITVTAY SPLGSPDRPW AKPEDPSLLE DPKIKEIAAK
     HKKTAAQVLI RFHIQRNVIV IPKSVTPARI VENIQVFDFK LSDEEMATIL SFNRNWRACN
     VLQSSHLEDY PFNAEY
//
